Berberine prevents progression from hepatic steatosis to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress

Zhiguo Zhang, Bo Li, Xiangjian Meng, Shuangshuang Yao, Lina Jin, Jian Yang, Jiqiu Wang, Huizhi Zhang, Zhijian Zhang, Dongsheng Cai, Yifei Zhang, Guang Ning

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The histological spectrum of nonalcoholic fatty liver diseases (NAFLD) ranges from hepatic steatosis to steatohepatitis and fibrosis. Berberine (BBR) is known for its therapeutic effect on obesity, hyperglycaemia and dyslipidaemia; however, its effect on NAFLD has yet to be thoroughly explored. Db/db mice and methionine-choline-deficient diet-fed mice were administered BBR via gavage. We found that BBR-treated mice were more resistant to steatosis in the liver than vehicle-treated mice and that BBR significantly reduced hepatic inflammation, fibrosis and lipid peroxides. The beneficial effect of BBR was associated with suppressing endoplasmic reticulum (ER) stress. Additionally, BBR decreased the free fatty acid-induced lipid accumulation and tunicamycin-induced ER stress in primary hepatocytes and hepatocyte cell lines. We demonstrated that BBR exhibited chaperone activity, reduced protein aggregation in vitro and alleviated tunicamycin-induced triglyceride and collagen deposition in vivo. Finally, we showed that BBR could reverse ER stress-activated lipogenesis through the ATF6/SREBP-1c pathway in vitro. These results indicated that BBR may be a new therapeutic strategy against hepatic steatosis and non-alcoholic steatohepatitis.

Original languageEnglish (US)
Article number20848
JournalScientific Reports
Volume6
DOIs
StatePublished - Feb 9 2016

Fingerprint

Berberine
Endoplasmic Reticulum Stress
Fatty Liver
Fibrosis
Liver
Tunicamycin
Hepatocytes
Sterol Regulatory Element Binding Protein 1
Lipogenesis
Lipid Peroxides
Therapeutic Uses
Dyslipidemias
Choline
Nonesterified Fatty Acids
Hyperglycemia
Methionine
Triglycerides
Collagen
Obesity
Diet

ASJC Scopus subject areas

  • General

Cite this

Berberine prevents progression from hepatic steatosis to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress. / Zhang, Zhiguo; Li, Bo; Meng, Xiangjian; Yao, Shuangshuang; Jin, Lina; Yang, Jian; Wang, Jiqiu; Zhang, Huizhi; Zhang, Zhijian; Cai, Dongsheng; Zhang, Yifei; Ning, Guang.

In: Scientific Reports, Vol. 6, 20848, 09.02.2016.

Research output: Contribution to journalArticle

Zhang, Z, Li, B, Meng, X, Yao, S, Jin, L, Yang, J, Wang, J, Zhang, H, Zhang, Z, Cai, D, Zhang, Y & Ning, G 2016, 'Berberine prevents progression from hepatic steatosis to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress', Scientific Reports, vol. 6, 20848. https://doi.org/10.1038/srep20848
Zhang, Zhiguo ; Li, Bo ; Meng, Xiangjian ; Yao, Shuangshuang ; Jin, Lina ; Yang, Jian ; Wang, Jiqiu ; Zhang, Huizhi ; Zhang, Zhijian ; Cai, Dongsheng ; Zhang, Yifei ; Ning, Guang. / Berberine prevents progression from hepatic steatosis to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress. In: Scientific Reports. 2016 ; Vol. 6.
@article{11f32ebb37b0405cbefba9cd6955806a,
title = "Berberine prevents progression from hepatic steatosis to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress",
abstract = "The histological spectrum of nonalcoholic fatty liver diseases (NAFLD) ranges from hepatic steatosis to steatohepatitis and fibrosis. Berberine (BBR) is known for its therapeutic effect on obesity, hyperglycaemia and dyslipidaemia; however, its effect on NAFLD has yet to be thoroughly explored. Db/db mice and methionine-choline-deficient diet-fed mice were administered BBR via gavage. We found that BBR-treated mice were more resistant to steatosis in the liver than vehicle-treated mice and that BBR significantly reduced hepatic inflammation, fibrosis and lipid peroxides. The beneficial effect of BBR was associated with suppressing endoplasmic reticulum (ER) stress. Additionally, BBR decreased the free fatty acid-induced lipid accumulation and tunicamycin-induced ER stress in primary hepatocytes and hepatocyte cell lines. We demonstrated that BBR exhibited chaperone activity, reduced protein aggregation in vitro and alleviated tunicamycin-induced triglyceride and collagen deposition in vivo. Finally, we showed that BBR could reverse ER stress-activated lipogenesis through the ATF6/SREBP-1c pathway in vitro. These results indicated that BBR may be a new therapeutic strategy against hepatic steatosis and non-alcoholic steatohepatitis.",
author = "Zhiguo Zhang and Bo Li and Xiangjian Meng and Shuangshuang Yao and Lina Jin and Jian Yang and Jiqiu Wang and Huizhi Zhang and Zhijian Zhang and Dongsheng Cai and Yifei Zhang and Guang Ning",
year = "2016",
month = "2",
day = "9",
doi = "10.1038/srep20848",
language = "English (US)",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Berberine prevents progression from hepatic steatosis to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress

AU - Zhang, Zhiguo

AU - Li, Bo

AU - Meng, Xiangjian

AU - Yao, Shuangshuang

AU - Jin, Lina

AU - Yang, Jian

AU - Wang, Jiqiu

AU - Zhang, Huizhi

AU - Zhang, Zhijian

AU - Cai, Dongsheng

AU - Zhang, Yifei

AU - Ning, Guang

PY - 2016/2/9

Y1 - 2016/2/9

N2 - The histological spectrum of nonalcoholic fatty liver diseases (NAFLD) ranges from hepatic steatosis to steatohepatitis and fibrosis. Berberine (BBR) is known for its therapeutic effect on obesity, hyperglycaemia and dyslipidaemia; however, its effect on NAFLD has yet to be thoroughly explored. Db/db mice and methionine-choline-deficient diet-fed mice were administered BBR via gavage. We found that BBR-treated mice were more resistant to steatosis in the liver than vehicle-treated mice and that BBR significantly reduced hepatic inflammation, fibrosis and lipid peroxides. The beneficial effect of BBR was associated with suppressing endoplasmic reticulum (ER) stress. Additionally, BBR decreased the free fatty acid-induced lipid accumulation and tunicamycin-induced ER stress in primary hepatocytes and hepatocyte cell lines. We demonstrated that BBR exhibited chaperone activity, reduced protein aggregation in vitro and alleviated tunicamycin-induced triglyceride and collagen deposition in vivo. Finally, we showed that BBR could reverse ER stress-activated lipogenesis through the ATF6/SREBP-1c pathway in vitro. These results indicated that BBR may be a new therapeutic strategy against hepatic steatosis and non-alcoholic steatohepatitis.

AB - The histological spectrum of nonalcoholic fatty liver diseases (NAFLD) ranges from hepatic steatosis to steatohepatitis and fibrosis. Berberine (BBR) is known for its therapeutic effect on obesity, hyperglycaemia and dyslipidaemia; however, its effect on NAFLD has yet to be thoroughly explored. Db/db mice and methionine-choline-deficient diet-fed mice were administered BBR via gavage. We found that BBR-treated mice were more resistant to steatosis in the liver than vehicle-treated mice and that BBR significantly reduced hepatic inflammation, fibrosis and lipid peroxides. The beneficial effect of BBR was associated with suppressing endoplasmic reticulum (ER) stress. Additionally, BBR decreased the free fatty acid-induced lipid accumulation and tunicamycin-induced ER stress in primary hepatocytes and hepatocyte cell lines. We demonstrated that BBR exhibited chaperone activity, reduced protein aggregation in vitro and alleviated tunicamycin-induced triglyceride and collagen deposition in vivo. Finally, we showed that BBR could reverse ER stress-activated lipogenesis through the ATF6/SREBP-1c pathway in vitro. These results indicated that BBR may be a new therapeutic strategy against hepatic steatosis and non-alcoholic steatohepatitis.

UR - http://www.scopus.com/inward/record.url?scp=84957569090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957569090&partnerID=8YFLogxK

U2 - 10.1038/srep20848

DO - 10.1038/srep20848

M3 - Article

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 20848

ER -